Pricing Log in Create free account
Friday 6 November 2026 Export CASIF’s income statement to Excel — free account

CASI Pharmaceuticals Inc.

CASIF Healthcare Biotechnology

CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024.

Revenue
−45.9%
EPS
+35.8%
Free cash flow
−23,251.7%
Total debt
+6.97%

Quarter to December 2025, against a year earlier

0.11 0.01 +10.00%
Market cap
$12.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−47.08
Beneish M
−8.73
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 89.10%

Capital & Financial Ratios $m

Size
Market Cap 12.39
Revenue ttm 20.71
Net income ttm (31.86)
Free cash flow ttm (70.46)
Net debt Q 16.02
Valuation
P/E 0.00
Forward P/E (0.09) (negative: loss-making)
Price / sales 0.09
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.15 (below 1: weak)
Debt / equity Q (0.34) (negative: negative equity)
Interest coverage Q (52.28)
Growth
Revenue growth Q −45.93% (below 0%: shrinking)
Operating income growth Q +14.71% (above 0%: growing)
EPS, this year −0.78% (below 0%: weak)
EPS, next year A +45.35% (at or above 15%: strong)
Revenue, next year A −34.87% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +18.42% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 7.1×; over the ten years it ranged from −0.5× in 2023 to 285× in 2018.
P/S against its own 10 years 0.48%
10-year low 10-year high
EV/Sales against its own 10 years 16.59%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 31 16 6 4
Receivables 10 15 4 3
Inventory 16 5 2 2
Other — — — —
59 40 13 10
2023 2024 2025 Q'26
Payables 4 3 1 1
ST’ Debt — 18 23 20
Other — — 1 1
17 36 50 67

Compound Annual Growth %

10y 5y 3y
Sales — 6.47% (21.68%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 (0.69) (0.86) (0.67) (0.48) (2.59)
’24 (0.71) (0.52) (0.55) (0.75) (2.56)
’23 (0.45) (0.77) (0.35) (0.45) (2.02)
’22 (0.60) (0.56) (0.38) (1.44) (3.01)
’21 (1.10) (0.50) (0.70) (0.40) (2.70)
’20 (0.90) (0.90) (1.40) (1.20) (4.40)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 6 4 3 7 21
’24 3 4 8 13 29
’23 8 10 9 7 34
’22 9 9 10 15 43
’21 6 7 8 9 30
’20 3 3 4 5 15
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — (21) (21)
’24 — (18) — (29) (29)
’23 — — — — (20)
’22 (4) (9) (7) (1) (21)
’21 (8) (7) (4) (8) (27)
’20 (5) (6) (7) (8) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — (21) (21)
’24 — (18) — (29) (29)
’23 — 0 — (2) (22)
’22 (7) (9) (7) (4) (27)
’21 (9) (8) (6) (13) (36)
’20 (4) (6) (6) (8) (25)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 4 15 30 43 34 29 21 21 +30.8% 13 13 — (19.3%)
Gross margin, % 0.00 0.00 0.00 4.74 37.20 58.38 63.28 59.19 39.06 48.65 48.65 +48.7 pt
EBT (9) (11) (27) (45) (48) (36) (37) (26) (38) (46) (46) +19.2%
EBT margin, % 0.00 0.00 0.00 (1,098.09) (313.79) (118.81) (86.83) (77.61) (133.40) (221.47) (221.47) (221.5) pt
Net income (9) (11) (27) (45) (48) (36) (40) (26) (39) (48) (32) +19.8%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.43 1.37 2.22 3.16 2.54 1.86 1.12 1.12 n/m
Earnings (1.70) (1.80) (3.20) (4.80) (4.40) (2.70) (3.01) (2.02) (2.56) (2.59) (2.70) +4.8%
Cash flow (1.08) (1.04) (3.37) (2.42) (2.34) (1.97) (1.55) (1.49) (1.91) (1.12) (3.72) +0.4%
Capex (0.01) (0.15) (0.13) (0.04) 0.11 (0.66) (0.40) (0.17) 0.02 0.00 (0.08) (19.8%)
Free cash flow (1.09) (1.19) (3.51) (2.47) (2.23) (2.63) (1.95) (1.66) (1.89) (1.12) (3.80) +0.3%
Book value 3.72 6.27 12.92 7.61 7.38 6.21 3.27 1.81 0.12 (2.01) 0.00 n/m
Shares, m 6 6 8 10 11 14 14 13 15 19 16 +14.3%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 71.35 21.52 3.61 0.58 2.85 1.52 0.76 0.09 14.6
P/B — — — 4.06 4.00 1.29 0.56 3.99 23.45 0.00 0.00 5.3
EV/Sales — — — 58.83 17.25 2.11 (0.50) 2.61 2.27 2.54 1.79 12.2
EV/FCF — — — (10.33) (10.58) (1.83) 0.82 (1.90) (1.15) (0.75) (0.52) (3.7)
Cash, $m
Cash, $m Operating cash flow (6) (6) (29) (23) (26) (27) (21) (20) (29) (21) (69) +14.7%
Capex 0 (1) (1) 0 1 (9) (5) (2) 0 0 (2) (8.5%)
Free cash flow (6) (7) (30) (24) (25) (36) (27) (22) (29) (21) (70) +14.6%
Balance, $m
Balance, $m Working capital 26 39 89 57 66 49 56 43 3 (36) (57) n/m
Net debt (26) (42) (84) (52) (65) (45) (51) (12) 2 18 16 n/m
Shareholders’ equity 21 39 109 73 82 85 45 24 2 (37) (58) n/m
Returns, %
Returns, % ROA (56.37) (29.58) (34.66) (42.61) (41.92) (27.56) (34.98) (31.44) (60.89) (121.17) 0.00 (64.8) pt
ROIC 0.00 0.00 (65.75) (140.09) (194.53) (66.19) 0.00 (127.53) (591.25) 0.00 0.00 0.0 pt
ROE (128.65) (36.31) (37.12) (50.46) (62.49) (44.15) (63.55) (78.44) (301.80) 271.28 0.00 +399.9 pt
People
People Employees 27 51 125 125 144 176 224 243 233 214 — +25.9%
Revenue/emp, $m 0.00 0.00 0.00 0.03 0.11 0.17 0.19 0.14 0.12 0.10 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 25 Oct 2026

CASI Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LPCN Lipocine Inc. $12.6M — (loss-making) — (loss-making) +1,898.32% (above 0%: growing) n/m +39.46% (above 0%: growing) 100.00% (37.93%) Compare
CASIF CASI Pharmaceuticals Inc. $12.4M — (loss-making) — (loss-making) −45.93% (below 0%: shrinking) n/m −23,251.69% (below 0%: shrinking) 51.14% (147.67%)
BOLT Bolt Biotherapeutics, Inc. $12.3M — (loss-making) — (loss-making) −99.72% (below 0%: shrinking) n/m +38.87% (above 0%: growing) 100.00% (167,480.00%) Compare
DARE Dare Bioscience, Inc. $12.3M — (loss-making) — (loss-making) +984.43% (above 0%: growing) n/m −30.23% (below 0%: shrinking) (70.56%) (1,582.93%) Compare
GUTS Fractyl Health, Inc. $11.9M — (loss-making) — (loss-making) −57.14% (below 0%: shrinking) n/m +25.34% (above 0%: growing) 100.00% 0.00% Compare
HIND Vyome Holdings, Inc. $11.4M — (loss-making) — (loss-making) −46.00% (below 0%: shrinking) n/m −195.04% (below 0%: shrinking) 43.33% (3,194.81%) Compare
PBM Psyence Biomedical Ltd. $11.2M 0.1× — — n/m −707.20% (below 0%: shrinking) — 0.00% Compare
CLRB Cellectar Biosciences, Inc. $10.9M — (loss-making) — −73.23% (below 0%: shrinking) n/m −17.49% (below 0%: shrinking) 0.00% 0.00% Compare
AEON AEON Biopharma, Inc. $9.4M — (loss-making) — — n/m −76.85% (below 0%: shrinking) — 0.00% Compare
Median of peers $11.7M — — −51.57% — −23.86% 71.67% (18.96%)

All 621 Biotechnology stocks →

CASI Pharmaceuticals Inc. (CASIF) Latest News

14 Aug

Impact 3 ·

25 Feb

Impact 5 · · ACCESS Newswire

15 Jan

Impact 4 · · ACCESS Newswire
Impact 3 · · ZacksZacksZacksInsider MonkeyZacksZacksZacksZacks

12 Jan

Impact 4 ·

23 Dec

Impact 3 · · ACCESS Newswire

11 Dec

Impact 3 · · ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

8 Dec

Impact 4 · · ACCESS Newswire

19 Nov

Impact 3 ·

14 Nov

Impact 3 · · ACCESS NewswireGuruFocus.comGuruFocus.comGuruFocus.comMotley FoolGuruFocus.com

10 Nov

Impact 3 · · ACCESS Newswire

3 Nov

Impact 4 ·

26 Sep

Impact 3 · · ACCESS NewswirePharmaceutical TechnologyClinical Trials ArenaClinical Trials ArenaSimply Wall St.Simply Wall St.GuruFocus.comBloomberg

8 Sep

Impact 4 · · ACCESS NewswireACCESS NewswireACCESS NewswireACCESS NewswireACCESS NewswireGlobeNewswireGlobeNewswire

3 Sep

Impact 3 · · ACCESS Newswire

2 Sep

Impact 3 ·

31 Aug

Impact 3 ·

29 Aug

Impact 3 ·

28 Aug

Impact 3 · · ACCESS Newswire

4 Aug

Impact 4 ·

21 Jul

Impact 4 ·

19 May

Impact 3 · · ACCESS Newswire

16 May

Impact 4 · · ACCESS Newswire

12 May

Impact 4 · · ACCESS Newswire

7 May

Impact 3 ·

3 Apr

Impact 4 ·

2 Apr

Impact 3 · · Simply Wall St.

31 Mar

Impact 3 ·

6 Feb

Impact 3 · · Simply Wall St.

6 Jan

Impact 4 ·
stockrow.com/CASIF · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com